This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Summit's ivonescimab and the results of the HARMONi-2 trial in Non-Small Cell Lung Cancer (NCSLC)

Ticker(s): SMMT, MRK

Who's the expert?

Institution: UC San Diego Health 

  • Professor of Medicine & Lung Cancer Unit Leader at Moores Cancer Center, UC San Diego.
  • Manages 250+ patients with lung cancer. 
  • Clinical practice and research focuses on lung cancer with a specific interest in cancer relating to females and non-smokers; active in numerous clinical trials.

Interview Goal
Discuss opinions on whether ivonescimab could potentially supplant Keytruda in 1L NSCLC

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.